No Data
No Data
Hedge Funds Investors in TScan Therapeutics, Inc. (NASDAQ:TCRX) See US$52m Decrease in Market Cap Last Week, Although Long-term Gains Have Benefitted Them.
Key Insights Given the large stake in the stock by institutions, TScan Therapeutics' stock price might be vulnerable to their trading decisions A total of 6 investors have a majority stake in the co
TScan Therapeutics Decline Means Insider Profits Down To US$54k
Express News | TScan Therapeutics Inc: Timothy Barberich Retires as Chair & Stephen Biggar Assumes Role of Chair
Express News | TScan Therapeutics Announces Updates to Its Board of Directors
The Analyst Landscape: 7 Takes On TScan Therapeutics
Analysts' ratings for TScan Therapeutics (NASDAQ:TCRX) over the last quarter vary from bullish to bearish, as provided by 7 analysts.The following table summarizes their recent ratings, shedding light
Buy Rating Affirmed for TScan Therapeutics Amidst Promising Clinical Advancements
No Data